Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price target dropped by research analysts at HC Wainwright from $27.00 to $20.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price suggests a potential upside of 171.74% from the stock’s previous close.
Other equities analysts have also issued reports about the company. Leerink Partners began coverage on Oric Pharmaceuticals in a report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Wells Fargo & Company cut their target price on Oric Pharmaceuticals from $25.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday. Citigroup boosted their price target on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wedbush reissued an “outperform” rating on shares of Oric Pharmaceuticals in a research note on Tuesday. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.18.
Read Our Latest Research Report on ORIC
Oric Pharmaceuticals Stock Performance
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). Equities research analysts expect that Oric Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.
Insider Buying and Selling at Oric Pharmaceuticals
In other news, CFO Dominic Piscitelli sold 14,000 shares of the stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the transaction, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. This trade represents a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 105,000 shares of company stock valued at $1,432,952. Corporate insiders own 5.70% of the company’s stock.
Institutional Investors Weigh In On Oric Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd acquired a new position in Oric Pharmaceuticals during the second quarter worth about $899,000. Defilade Capital Management L.P. bought a new stake in Oric Pharmaceuticals in the first quarter worth about $10,680,000. Squarepoint Ops LLC bought a new stake in Oric Pharmaceuticals in the second quarter worth about $3,729,000. Blue Owl Capital Holdings LP bought a new stake in Oric Pharmaceuticals in the second quarter worth about $4,332,000. Finally, Bank of America Corp DE acquired a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $11,675,000. Institutional investors own 95.05% of the company’s stock.
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading
- Five stocks we like better than Oric Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
